National Survey on Hypertension - Full Text View

National Survey on Hypertension (SERENITE)

This study is currently recruiting participants.

Verified by AstraZeneca, December 2008

First Received: December 5, 2008 No Changes Posted

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00804167

Purpose

Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage

Condition
Hypertension

MedlinePlus related topics: High Blood Pressure

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional
Official Title:	Profile of Hypertensive Patients Aged of 75 Years and Older Seen in General Practitioner According to Their Renal Damage.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage [ Time Frame: once ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	4500
Study Start Date:	December 2008
Estimated Study Completion Date:	April 2009

Eligibility

Ages Eligible for Study:	75 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

The first 3 consecutive patients seen during the GP's visit with a diagnosis of Hypertension and with renal damage

Criteria

Inclusion Criteria:

Male or female aged 75 years or older
With a diagnosis of Hypertension treated or not, seen in general practitioner consultation
Who has given his/her consent to participate to the study.

Exclusion Criteria:

Patient who participated to a clinical trial

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00804167

Contacts

Contact: AstraZeneca France Clinical Study, Information

01 41 29 40 00

stephan.becouarn@astrazeneca.com

Show 1300 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Alain Castaigne, Medical Director

AstraZeneca

More Information

No publications provided

Responsible Party:	AstraZeneca Pharmaceuticals ( Alain Castaigne, Medical Director )
Study ID Numbers:	NIS-CFR-DUM-2008/1
Study First Received:	December 5, 2008
Last Updated:	December 5, 2008
ClinicalTrials.gov Identifier:	NCT00804167 History of Changes
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

Hypertensive patients aged of 75 years and older
renal damage
Clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage

Study placed in the following topic categories:

Vascular Diseases
Hypertension

Additional relevant MeSH terms:

Vascular Diseases
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on May 07, 2009